- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02524366
A Study of Transcorporal Versus Standard Artificial Urinary Sphincter Placement
A Randomized Study of Transcorporal Versus Standard Artificial Urinary Sphincter Placement
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The AUS is the gold standard for treatment of severe SUI, particularly in patients following surgical resection of the prostate for prostate cancer. In fact, severe urinary incontinence can be the most distressing complication following radical prostatectomy and results in a negative impact on quality of life (Haab, Trockman et al. 1997). Placement of an AUS has been shown to result in an improved quality of life in these patients. AUSs are small devices that prevent urinary flow via compression of the urethra, thus mimicking the native urinary sphincter. They have been available, albeit with occasional improvements or changes in design, since the 1970's. When placed in the standard fashion (ST) a small incision is made in the patient's perineum or scrotum and a fluid-filled cuff is placed around the bulbar urethra (the portion of the urethra between the bladder neck and penis). Connected to the cuff with tubing, is a balloon filled with fluid that is placed behind the pubic bone or in the space between the peritoneum and abdominal muscles. A control pump is placed in the scrotum and allows the device to cycle, thus either exerting pressure to close off the urethra or releasing pressure to allow the urethra to open and the patient to void. 73-76% of patients will experience dramatic improvement in incontinence with very minimal leakage (0-1 pads per day) and 88-89% report significant improvement or cure. Two years following implant, 9% of patients will experience a significant decline in the functionality of the device and report severe incontinence. At 5 years, 28% will need to undergo revision of the device (Dalkin, Wessells et al. 2003). Long-term complications associated with the device include urethral erosion in 5% of cases, urethral atrophy, infection, and mechanical failure of the device.
Patients undergoing radical prostatectomy frequently undergo radiation treatment during the course of their illness. Radiation to the pelvic region is responsible for compromising blood flow to the urethra and fibrosis. As a result these patients are at a moderate risk of developing complications and ultimately failure of the device necessitating removal and/or replacement. Factors that put patients in a high-risk category include a history of urethroplasty for urethral stricture, a history of a prior artificial urinary sphincter, and a history of open surgery for bladder neck contractures (scarring at the entrance to the bladder). Patients who develop a complication as listed above, often require a replacement AUS in a different location than the first cuff. This is done more distally in the penis where the urethra is narrower and there is less tissue to fill the cuff. This puts them at a higher risk for further complications. Several authors have recently published their experience with a modification to the standard technique in patients at a high risk for failure (Guralnick, Miller et al. 2002) (Aaronson, Elliott et al. 2008). The modified technique, termed transcorporal placement (TC), has been shown to be beneficial in this subset of patients. In one study, 28% of high-risk patients with ST placement developed erosion or infection, which required explanting the device compared with 13% in the TC group (4). Continence was also better in this high-risk group when TC placement was used, compared with ST, 89% vs 61%. TC placement also reduces the risk of injury to the urethra during surgery. Unlike in ST, TC placement involves placing the device around the urethra but also incorporating a flap of the tough tunica albigunea. The same incision is made as for the ST approach, and then an incision is made in each corpus cavernosum (cylinders of tissue that allow for erection). This allows the cuff to be placed around both the urethra and through the lining of the corporal bodies, increasing the bulk of tissue behind the urethra to protect it from erosion.
It has been suggested that placing the cuff near the erectile tissues might cause erectile dysfunction and as a result few surgeons perform this procedure on potent patients. However, scant data exist to support or refute this hypothetical effect on erectile function. Despite its success in patients at high risk of erosion, the TC approach has never been adequately tested in patients without a high risk of failure. It is unknown if this is a technique that only benefits this subset of patients or whether all patients might experience better long-term continence with less risk for erosion.
Study Objectives
The purpose of this study is to improve long-term patient outcomes and reduce complications and morbidity in patients with male SUI who are candidates for AUS insertion after radiation. The results from this study will provide clinicians evidence for superiority of either the ST or TC AUS. Our null hypothesis is that there is no difference in outcomes (as defined below) for AUS done in a TC vs. ST method. The alternative hypothesis is that one procedure is inferior/superior to the other.
Primary endpoint: AUS revision or removal surgery. These include surgery for mechanical failure, cuff erosion, impending erosion (discretion of surgeon), urethral atrophy, urinary incontinence and persistent retention due to small cuff.
Secondary endpoints:
Rate of post-operative urinary retention. Urinary retention defined as urinary catheter placement for more than 5 days in the period between AUS implantation and AUS activation (typically 4-8 weeks postoperatively) Incontinence at 3 months post-operatively measured using 24-hour pad weight test. Erectile function at 3 months as measured via the Sexual Health Inventory for Men (SHIM) Incontinence and QoL impact at 3 months as measured by the Incontinence Severity Index (ISI) and the Incontinency Impact Questionnaire Short From (IIQ-7)
Study Type
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- University of Minnesota Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Men undergoing an AUS procedure
- History of pelvic radiation for prostate or other cancer
- No spontaneous erections and no erections with oral erectogenic agents
- Subjects able to consent for themselves
Exclusion Criteria:
- prior urethroplasty
- prior urethral erosion of AUS
- history of penile prosthesis placement or explantation
- concomitant placement of penile prosthesis at the time of AUS placement
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Transcorporal AUS
The artificial urinary sphincter is placed through the tunica albuginea of the corpora cavernosa in order to theoretically provide a protective backing on the urethra.
|
|
Active Comparator: Standard AUS
The artificial urinary sphincter is placed in the standard fashion.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
AUS Removal/Revision
Time Frame: 2 years
|
We will record the incidence of any repeat AUS surgery for mechanical failure, cuff erosion, impending erosion (discretion of surgeon), urethral atrophy, urinary incontinence and persistent retention due to small cuff.
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Urinary Retention
Time Frame: 8 weeks
|
Incidence of post-operative urinary retention defined as having a urethral catheter placed or re-placed any time after 5 days post-operative.
|
8 weeks
|
Incontinence
Time Frame: 3 months
|
24 hour pad weight test will be administered at 3 months.
|
3 months
|
Incontinence Quality of Life
Time Frame: 3 months
|
Incontinence Severity Index and Incontinency Impact Questionnaire Short Form questionnaire will be administered
|
3 months
|
Sexual Function
Time Frame: 3 months
|
Sexual Health Inventory for Men will be administered
|
3 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Sean Elliott, MD, University of Minnesota
Publications and helpful links
General Publications
- Haab F, Trockman BA, Zimmern PE, Leach GE. Quality of life and continence assessment of the artificial urinary sphincter in men with minimum 3.5 years of followup. J Urol. 1997 Aug;158(2):435-9.
- Dalkin BL, Wessells H, Cui H. A national survey of urinary and health related quality of life outcomes in men with an artificial urinary sphincter for post-radical prostatectomy incontinence. J Urol. 2003 Jan;169(1):237-9. doi: 10.1097/01.ju.0000040621.68116.4e.
- Guralnick ML, Miller E, Toh KL, Webster GD. Transcorporal artificial urinary sphincter cuff placement in cases requiring revision for erosion and urethral atrophy. J Urol. 2002 May;167(5):2075-8; discussion 2079.
- Aaronson DS, Elliott SP, McAninch JW. Transcorporal artificial urinary sphincter placement for incontinence in high-risk patients after treatment of prostate cancer. Urology. 2008 Oct;72(4):825-7. doi: 10.1016/j.urology.2008.06.065. Epub 2008 Aug 26.
- Simhan J, Morey AF, Zhao LC, Tausch TJ, Scott JF, Hudak SJ, Mazzarella BC. Decreasing need for artificial urinary sphincter revision surgery by precise cuff sizing in men with spongiosal atrophy. J Urol. 2014 Sep;192(3):798-803. doi: 10.1016/j.juro.2014.03.115. Epub 2014 Apr 16.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Elliott TC vs ST AUS
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stress Urinary Incontinence
-
University of New MexicoRecruitingUrinary Incontinence | Urge Incontinence | Stress Incontinence, FemaleUnited States
-
University of California, San FranciscoNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Stanford...CompletedUrinary Incontinence, Stress | Urge Incontinence | Urinary Stress Incontinence | Stress Incontinence, Urinary | Stress Incontinence | Stress Incontinence, Female | Urgency UrinaryUnited States
-
Juna d.o.o.CompletedFemale Stress Urinary Incontinence | Mixed Incontinence, Urge and Stress
-
Université de SherbrookeRecruitingUrinary Incontinence | Urinary Stress Incontinence | Post-Prostatectomy Incontinence | Stress Incontinence, MaleCanada
-
Far Eastern Memorial HospitalRecruitingWomen With Stress Urinary IncontinenceTaiwan
-
University Magna GraeciaUnknownStress Urinary IncontinenceItaly
-
Hadassah Medical OrganizationCompletedUrinary Stress Incontinence (SI)Israel
-
University of California, IrvineWithdrawnStress Urinary IncontinenceUnited States
-
Eli Lilly and CompanyBoehringer IngelheimCompleted
-
Eli Lilly and CompanyBoehringer IngelheimCompletedUrinary Stress IncontinenceUnited States
Clinical Trials on Artificial Urinary Sphincter
-
UroMems SASRecruitingUrinary Incontinence,StressFrance
-
University of California, San FranciscoBaylor College of Medicine; University of California, San Diego; New York University and other collaboratorsTerminatedUrinary Stress IncontinenceUnited States
-
GT Urological, LLCCompletedMale Stress Urinary IncontinenceAustralia, Czechia, New Zealand
-
Myopowers Medical Technologies France SASEVAMED; Affluent MedicalNot yet recruitingStress Urinary IncontinenceSpain, Czechia
-
UroMems SASActive, not recruitingUrinary Incontinence,StressFrance
-
Fondazione Policlinico Universitario Agostino Gemelli...Recruiting
-
Boston Scientific CorporationActive, not recruitingStress Urinary IncontinenceUnited States, Australia
-
University of LorraineCompletedChild, Only | Neurogenic Bladder | Spina Bifida | Bladder DysfunctionFrance
-
Université de SherbrookeRecruitingUrinary Incontinence | Urinary Stress Incontinence | Post-Prostatectomy Incontinence | Stress Incontinence, MaleCanada
-
Stanford UniversityWithdrawn